The effect of deletion of the V3 loop of gp120 on cytotoxic T cell responses and HIV gp120-mediated pathogenesis

Journal of Immunology

Volumn 160, Issue 11, 1998, Pages 5676-5683

  Kmieciak, Dariusz ^a,f,g   Wasik, Thomas J ^a,g   Teppler, Hedy ^a,h   Pientka, Janet ^a,h   Hsu, Susan H ^b   Takahashi, Hidemi ^c   Okumura, Ko ^d   Kaneko, Yutaro ^e   Kozbor, Danuta ^a,f,i  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Histocompatibility Laboratory   (United States)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e AJINOMOTO CO INC   (Japan)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ Ctr Neurovirol and Neurooncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GENE PRODUCT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SYNCYTIUM; VIRUS ENVELOPE; VIRUS GENE;

ADULT; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; CELL LINE, TRANSFORMED; GENE PRODUCTS, ENV; GIANT CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MUTAGENESIS, SITE-DIRECTED; SEQUENCE DELETION; T-LYMPHOCYTES, CYTOTOXIC; VACCINIA VIRUS;

EID: 0032104009     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Koup, R. A., J. T. Safrit, Y. Can, C. A. Andrews, G. McLeod, W. Borkowski, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650.
2. Klein, M. R., C. van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. M. Keet, J.-K. M. Eeftinck-Schattenkerk, A. D. M. E. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitu dinai analysis of rapid progressons and long-term asymptomatics. J. Exp. Med. 181:1365.
3. Pantaleo, G., S. Menzo, M. Vaccareza, C. Graziosi, O. J. Cohen, J. F. Demarest, D. Montefiori, J. M. Orenstein, C. Fox, L. K. Schrager, J. B. Margolick, S. Buchbinder, J. V. Giorgi, and A. S. Fauci. 1995. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332:209.
4. Rinaldo, C., X.-L. Huang, Z. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, and P. Gupta. 1995. High levels of antihuman immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J. Virol. 69:5838.
5. Rowland-Jones, S., J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, T. Corrah, M. Takiguchi, T. Schultz, A. McMichael, and H. Whittle. 1995. HIV-specific cytotoxic T-cefis in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59-64.
6. Rowland-Jones. S., D. F. Nixon, M. C. Aldhous, F. Gotch, K. Ariyoshi, N. Hailam, J. S. Kroll, K. Froeber, and A. McMichael. 1993. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 341:860.
7. Phillips, R. E., S. Rowland-Jones, D. F. Nixon, F. M. Gotch, J. P. Edwards, A. O. Ogunlesi, J. G. Elvin, J. A. Rothbard, C. R. Bangham, and C. R. Rizza. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453.
8. Klenerman, P., S. Rowland-Jones, S. McAdam, J. Edwards, S. Daenke, D. Lalloo, B. Koppe, W. Rosenberg, D. Boyd, A. Edwards, P. Giangrande, R. E. Phillips, and A. J. McMichael. 1994. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369:403.
9. Klenerman, P., U. C. Meier, R. E. Phillips, and A. J. McMichael. 1995. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur. J. Immunol. 25:1927.
10. + T cell turnover. Science 274:1543.
11. Siliciano, R. F. 1996. The role of CD4 in HIV envelope-mediated pathogenesis. Curr. Top. Microbiol. Immunol. 205:159.
12. Laurent-Crawford, A. G., B. Krust, Y. Riviere, C. Desgranges, S. Muller, M. P. Kieny, C. Dauguet, and A. G. Hovanessian. 1993. Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 Cells. AIDS Res. Hum. Retroviruses 9:761.
13. lck. J. Exp. Med. 183:39.
14. Finkel, T. H., G. Tudor-Williams, N. K. Banda, M. F. Cotton, T. Curiel, C. Monks, T. W. Baba, R. M. Ruprecht, and A. Kupfer. 1995. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIV-infected lymph nodes. Nat. Med. 1:129.
15. Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. 1991. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71.
16. Wyatt, R., M. Thali, S. Tilley, A. Pinter, M. Posner, D. Ho, J. Robinson, and J. Sodroski. 1992. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J. Virol. 66:6997.
17. Earl, P. L., A. W. Hugin, and B. Moss. 1990. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J. Virol. 64:2448.
18. Dupuis, M., S. M. Kundu, and T. Merigan. 1995. Characterization of HLA-A*0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein. J. Immunol. 155:2232.
19. + cytotoxic lymphocytes by free antigenic peptide: a selfveto mechanism? J. Exp. Med. 183:879.
20. Otvos, L., Jr., L. Urge, Z. Q. Xiang, G. R. Krivulka, L. Nagy, G. I. Szenderei, and H. C. Ertl. 1994. Glycosylation of synthetic T helper cell epitopic peptides influences their antigenic potency and conformation in a sugar location-specific manner. Biochim. Biophys. Acta 1224:68.
21. Kozbor, D., and J. C. Roder. 1981. Requirements for the establishment of hightitered human monoclonal antibodies against tetanus toxoid using the EpsteinBarr virus technique. J. Immunol. 127:1275.
22. Tsomides, T. J., A. Aldovini, R. P. Johnson, B. D. Walker, R. A. Young, and H. N. Eisen. 1994. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type I. J. Exp. Med. 180:1283.
23. Kalams, S. A., R. P. Johnson, A. K. Trocha, M. J. Dynan, H. S. Ngo, R. T. D'Aquila, J. T. Kumick, and B. D. Walker, Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire. J. Exp. Med. 179:1261.
24. Koup, R. A., C. A. Pikora, K. Luzuriaga, D. B. Brettler, E. S. Day, G. P. Mazzara, and J. L. Sullivan. 1991. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities. J. Exp. Med. 174:1593.
25. Fazekas de St. Groth, S. 1982. The evaluation of limiting dilution assays. J. Immunol. Methods 49:R11.
26. Posner, M. R., T. Hideshima, T. Cannon, M. Mukherjee, K. H. Mayer, and R. A. Byrn. 1991. An IgG human monoclonal antibody that reacts with HIV-1/ GP120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146:4325.
27. Moore, J. P., M. Thali, B. A. Jameson, F. Vignaux, G. K. Lewis, S. W. Poon, M. Charles, M. S. Fung, B. Sun, P. J. Durda, L. Akerblom, B. Wahren, D. D. Ho, Q. J. Sattentau, and J. Sodroski. 1993. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J. Virol. 67:4785.
28. Forthal, D. N., G. Landucci, M. K. Gorny, S. Zolla-Pazner, and W. E. Jr. Robinson. 1995. Functional activities of 20 human immunodeficiency virus type 1 (HlV-1)-specific human monoclonal antibodies. AIDS Res. Hum. Retroviruses 11:1095.
29. Callahan, L. N., M. Phelan, M. Mallison, and M. A. Norcross. 1991. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J. Virol. 65:1543.
30. + T cell populations. Eur. J. Immunol. 25:2907.
31. Banda, N. K., J. Bernier, D. K. Kurahara, R. Kurrle, N. Haigwood, R. P. Sekaly, and T. H. Finkel. 1992. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J. Exp. Med. 176:1099.
32. Wyatt, R., N. Sullivan, M. Thali, H. Repke, D. Ho, J. Robinson, M. Posner, and J. Sodroski. 1993. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557.
33. Alexander-Miller, M. A., K. C. Parker, T. Tsukui, C. D. Pendleton, J. E. Coligan, and J. A. Berzofsky. 1996. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Int. Immunol. 8:641.
34. Vogel, T., R. Kurth, and S. Norley. 1994. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequence. J. Immunol. 153: 1895.
35. Giovarelli, M., A. Santoni, C. Jemma, T. Musso, A. M. Giuffrida, G. Cavallo, S. Landolfo, and G. Forni. 1988. Obligatory role of IFN-γ in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. J. Immunol. 41:2831.
36. Romagnani, S. 1991. Human Th1 and Th2 subsets: doubt no more. Immunol. Today 12:256.
37. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadjanyan, L. Gilbert, M. L. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. V. Williams, Y. Refaeli, R. B. Ciccarelli, D. McCallus, L. Coney, and D. B. Weiner. 1997. Protection of chimpanzees from high-dose heterologous HTV-1 challenge by DNA vaccination. Nat. Med. 3:526.
38. Wu, Y., L. Duan, M. Zhu, B. Hu, S. Kubota, O. Bagasra, and R. J. Pomerantz. 1996. Binding of intracellular anti-rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition. J. Virol. 70:3290.
39. Parren, P. W. H. I., D. R. Burton, and Q. J. Sattentau. 1997. HIV-1 antibody: debris or virion? Nat. Med. 3:366.
40. Albert, J., B. Abrahamsson, K. Nagy, E. Aurelius, H. Gaines, G. Nystrom, and E. Fenyo. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by aulologous sera. AIDS 4:107.
41. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live-attenuated SIV vaccine with deletion in the nef gene. Science 258:1938.
42. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:3724.
43. Johnson, R. P., R. L. Glickman, J. Q. Yang, A. Kaur, J. T. Dion, M. J. Mulligan, and R. C. Desrosiers. 1997. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J. Virol. 71:7711.
44. Baba, T. W., Y. S. Jeong, D. Penninck, R. Bronson, M. F. Greene, and R. M. Ruprecht. 1995. Pathogenicity of life, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820.
45. Wyand, M. S., K. H. Manson, A. A. Lackner, and R. C. Desrosiers. 1997. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat. Med. 3:32.
46. Desrosiers, R. C. 1994. Yes, it is time to consider use of a live-attenuated virus vaccine against HIV-1. J. NIH Res. 6:54.
47. Bolognesi, D. P. 1994. Not yet, it is too early to consider use of a live-attenuated virus vaccine against HIV-1. J. NIH Res. 6:55.
48. Ciernik, I. F., J. A. Berzofsky, and D. P. Carbone. 1996. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156:2369.
49. Johnson, R. P., S. C. Hammond, A. Trocha, R. S. Siliciano, and B. Walker. 1994. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. AIDS Res. Hum. Retroviruses 10:S73.
50. Winer, B. J. 1971. Statistical Principals in Experimental Design. McGraw-Hill, New York, pp. 309-428.